Third Rock-Backed Abata Secures $95M for T-reg Cell Therapy Against MS

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Lab Supply Shortages Persist, Slowing Down Everyday Experiments
Bright Peak Therapeutics Raises $107M to Advance Cytokine Engineering
Stablix, Seeking to Stabilize Instead of Degrade Proteins, Raises $63M
Appia Bio Seeks Off-the-Shelf Cancer Therapy With Rare iNKT Cells